

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

-----  
FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): January 19, 2000

Neoprobe Corporation

-----  
(Exact Name of Registrant as Specified in Charter)

Delaware	0-26520	31-1080091
-----	-----	-----
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

425 Metro Place North, Suite 300, Dublin, Ohio	43017
-----	-----
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code (614) 793-7500

-----  
(Former Name or Former Address, if Changed Since Last Report)  
Item 2. Acquisition or Disposition of Assets.

-----  
On January 19, 2000, the Registrant sold its equity investment in XTL Biopharmaceuticals Ltd. ("XTL"), consisting of 2 Class A Common Shares, par value \$.020 per share, of XTL and 170,650 Class A Preferred Shares, par value \$.020 per share, of XTL, to an Israeli investor for \$1,500,000.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

-----  
(a) Financial Statements of Business Acquired.

Not applicable.

(b) Pro Forma Financial Information.

Not applicable.

(c) Exhibits.

None

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEOPROBE CORPORATION

Date: January 27, 2000

By: /s/ David C. Bupp

-----  
David C. Bupp, President  
Chief Executive Officer